Pelthos Therapeutics Inc. (PTHS): auditor change — Pelthos Therapeutics dismisses CFO Knuettel, appoints Grant Thornton as auditor

Pelthos Therapeutics Inc.

CFO Francis Knuettel II terminated effective April 10, 2026; separation agreement provides $430,000 severance (12 months salary) and accelerated vesting of 59,500 options and 19,525 RSUs.
Auditor change: CBIZ CPAs dismissed, Grant Thornton LLP engaged for FY2026; no disagreements or reportable events reported.
Knuettel's equity acceleration: 59,500 options and 19,525 RSUs vest; options exercisable until Jan 15, 2027, unvested portion forfeited.
Separation agreement includes release of claims, confidentiality, non-disparagement, and cooperation; effective after 7-day revocation period.

item 4.01 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Francis Knuettel II

Chief Financial Officer, Treasurer and Secretary

PTHS · Pelthos Therapeutics Inc.

Effective: 2026-04-10
Filed: May 21, 2026, 5:00 PM ET

the Board terminated Francis Knuettel II from his position as Chief Financial Officer, Treasurer and Secretary of the Company, effective April 10, 2026.

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Pelthos Therapeutics Inc. engaged Grant Thornton LLP as its auditor.

Action: engagement
Auditor: Grant Thornton LLP

Exact text from the filing

Also on May 16, 2026, the Audit Committee approved the engagement of Grant Thornton LLP (“Grant Thornton”), as its new independent registered public accounting firm.

View on SEC.gov

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Pelthos Therapeutics Inc. dismissed CBIZ CPAs P.C. as its auditor.

Action: dismissal
Auditor: CBIZ CPAs P.C.
Successor: Grant Thornton LLP

Exact text from the filing

On May 16, 2026, the Audit Committee (the “Audit Committee”) of the Board of Directors (the “Board”) of Pelthos Therapeutics Inc. (the “Company”) approved the dismissal of CBIZ CPAs P.C. (“CBIZ”), as the Company’s independent registered public accounting firm.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Francis Knuettel II was terminated as Chief Financial Officer, Treasurer and Secretary at Pelthos Therapeutics Inc..

Action: terminated
Role: Chief Financial Officer, Treasurer and Secretary

Exact text from the filing

the Board terminated Francis Knuettel II from his position as Chief Financial Officer, Treasurer and Secretary of the Company, effective April 10, 2026.

View on SEC.gov

6 auditor changes filed in the last 30 days. Browse all auditor changes →

Pelthos Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001919246-26-000078

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.